DREEM

Their core work

DREEM is a Paris-based digital health SME that develops wearable technology for measuring sleep quality, fatigue, and physical activity — the kind of objective, sensor-derived data that clinical researchers need but rarely have access to outside a hospital lab. In both H2020 projects, they contribute as a technology provider, supplying remote measurement capabilities that allow patients to be monitored from home rather than clinical sites. Their participation in IDEA-FAST places them squarely in the emerging field of digital endpoint validation: defining and proving that wearable-derived signals can substitute for traditional clinical measures in regulatory submissions. The combination of remote data collection (Trials@Home) and disease-specific endpoint validation (IDEA-FAST) positions them as a specialist bridge between consumer neurotechnology and clinical-grade research infrastructure.

What they specialise in

How they've shifted over time

Both projects began in 2019, so there is no meaningful chronological gap to measure true evolution — DREEM entered the H2020 programme with two concurrent engagements rather than a progression over years. That said, the keyword shift between the two projects tells a real story: the first project (Trials@Home) is methodological, focused on how to run trials remotely, while the second (IDEA-FAST) is disease-specific, focused on what to measure and whether those measurements are valid. This suggests DREEM moved — or was recruited — from providing trial infrastructure to providing validated clinical signals in specific disease areas. The trajectory points toward regulatory-grade digital biomarker development rather than general remote trial logistics.

DREEM is moving toward validation of specific wearable-derived biomarkers in chronic disease — a commercially strategic position as regulators begin accepting digital endpoints in drug approval submissions.

How they like to work

DREEM has participated in two large multi-country RIA consortia without ever taking a coordinator role, which is consistent with an SME that contributes a proprietary technology component and relies on academic or clinical partners to lead the scientific agenda. Both consortia are large — collectively connecting them to 82 partners across 19 countries — suggesting they are comfortable operating as a specialist node in complex international networks. For potential partners, this means DREEM is likely to be a reliable and technically focused contributor, but should not be expected to carry project management or consortium governance responsibility.

Despite only two projects, DREEM has accumulated 82 unique consortium partners spanning 19 countries — a reflection of the large RIA consortia they joined rather than a broad independent network. Their connections are concentrated in European clinical and academic research institutions active in neurology, rheumatology, and clinical trial methodology.

What sets them apart

DREEM sits at an unusual intersection: a commercial SME with a deployable wearable product that has been validated inside large academic clinical research consortia — a combination that is genuinely rare among H2020 participants. For a consortium builder, they offer something that universities and hospitals cannot: a production-ready device with real-world data collection capability that can be shipped to patients across multiple countries. Their dual involvement in both decentralised trial methodology and disease-specific endpoint validation means they understand both the operational and the scientific demands of remote monitoring at scale.

Highlights from their portfolio

• Trials@Home
  Largest funding received (EUR 129,948) and participation in a dedicated Center of Excellence for remote decentralised clinical trials — a high-profile methodological initiative with direct regulatory relevance.
• IDEA-FAST
  Longest project duration (to 2026) targeting validation of digital endpoints across two distinct chronic disease areas — neurodegenerative and immune-mediated — which is an unusually broad validation scope for a single consortium effort.